Latest news and press releases about Immunovant, Inc. (IMVT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases.
Price
| Price | $36.38 |
| Market Cap | $7.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 9.99 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 97.10% |
| Operating Margin | -7877.46% |
| Net Margin | -7585.86% |
Related companies: ACAD · AKRO · CRNX · DYN · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of IMVT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks